For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.
Two types of HAV vaccines are currently available internationally:
1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and in adult dose (1 ml).
2. Live attenuated vaccines (based on H2 or LA-1 HAV strains): These vaccines are manufactured and used mainly in China and sporadically in the private sector in India.
Scope of the Report:
Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.
The classification of Hepatitis A Vaccine includes Inactivated Vaccine, Live Attenuated Vaccine, and the sales proportion of Inactivated Vaccine in 2017 is about 70.8%, and the proportion is increasing trend from 2013 to 2018.
Inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and in adult dose (1 ml).
The worldwide market for Hepatitis A Vaccine is expected to grow at a CAGR of roughly 2.8% over the next five years, will reach 770 million US$ in 2024, from 650 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Hepatitis A Vaccine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- GSK
- Merck
- Sanofi
- Sinovac
- Zhejiang Pukang
- Changchun Institute of Biological
- Kaketsuken
- IMBCA
- ChangSheng
- Convac
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Inactivated Vaccine
- Live Attenuated Vaccine
Market Segment by Applications, can be divided into
- Government Institution
- Private Sector
- Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hepatitis A Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Hepatitis A Vaccine, with price, sales, revenue and global market share of Hepatitis A Vaccine in 2017 and 2018.
Chapter 3, the Hepatitis A Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hepatitis A Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Hepatitis A Vaccine market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Hepatitis A Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.